Cel Sci Corporation New (CVM)

You never learn

Whats wrong with you? You bought more shares?

Cant fix stupid

Yesterday's daily short sale volume was 50.41% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market. The short borrow fee has increased to 57.91%!! and the number of currently shorted shares has increased to 269'000 shares. Furthermore, the short shares availability is down to 300 shares. With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!

Let's hope that you are correct, that something doesn't happen to undermine the Saudi deal, and that - indeed - those holding short get their gooses cooked.

Yesterday's daily short sale volume was 65.45% (as reported by FINRA) and it seems that the shorts are trying hard to manipulate the market, but the PPS went up 2.8%! The short borrow fee increased to 37.66% and the number of currently shorted shares has increased to 269'000 shares. Further, the short shares availability is currently down to 5000 shares. With the recent SFDA and partner developments, it should just be a matter of time until Multikine will be approved and the heavy manipulation by the shorts will come to an end. I am so happy for all the cancer patients who will hopefully soon be able to profit from Multikine! GLTAL!!

Best to negotiate when strong: If you are broke and in a hurry, and the person you are negotiating with knows it, then you are in a bad position. CVM claims to be in the middle of negotiating. The offering, which is now over with, puts them in a much better position. Other criticisms that I have heard are persuasive, and this all may have been a head fake for survival, but just saying that the offering does make sense if they really are dealing with big dogs in Saudi Arabia.

Yep

NEW PR
So they have not yet filed for Breakthrough Medicine Designation.

And the SFDA rules are clear that the designation is not an approval. It allows for a "Breakthrough Application" to be filed.

A lot of spin and lies here be the team.

Heis

"Signed contract"

Huh?

I read "expected to be signed"

Moron

Why didnt this fication to be signed partner in SA offer up a measly $5M

Why?

Moron
Tell your mom sushi says hi

Or was it just about dumping shares again?
I haven't looked at all their deals, but there is last one before CVM

https://www.think-equity.com/transactions

$BMNR

Why didn't CVM do a private placement with those Saudi Funds who supposedly have an interest?In many ways that would have made quite a bit more sense.

And this is why I stated earlier today that I wondered where this would settle after the initial burst of enthusiasm. Now - we have a better idea. That $3.82 offer set a new floor range is my guess.

Quite the rally today. Lasted almost 5 hours!!
I wonder who made the money dumping?
Opened up about $3.20 per share, now down .22....any of you all get fleeced today?

Awesome. If the stock goes up another $153, I'll break even.

good point

They may have done that as well…we will find out

Offering Priced at the Market.
Had to do a double check. Offering Price at $3.82 was the closing price yesterday the 10th.

The announcement of a Partnership Agreement stated "Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market."
Why didn't CVM do a private placement with those Saudi Funds who supposedly have an interest?

And raising ONLY $5.7M to fund Cancer Immunotherapy development??

Should have been at least $57M... ???

Exwannabe - SMH - Dont worry about this..

Just guess who is coming for you...

Karmic Resonance & Everyone been watching....

Shares Halted after Offering news. Last Trade before halt at $5.0801

CEL-SCI Announces $5.7M Best-Efforts Offering Of 1.5M Shares At $3.82/Share; To Fund Cancer Immunotherapy Development
12:17 PM EDT, July 11, 2025
12:17 PM EDT, July 11, 2025 (Benzinga Newswire)



CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock is being sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $5.7 million. The offering is expected to close on July 14, 2025, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.

ThinkEquity is acting as the sole placement agent for the offering.

Anyone else wondering why they had to work with a Saudi pharma company? No US, no Canada, no England?..
Could it be because its much tougher to verify?

While CEL-SCI has the option of filing for Breakthrough Medicine Designation directly, the Company made a strategic decision to collaborate with its local partner for the regulatory filing and subsequent commercial distribution in Saudi Arabia.

Feel free to discuss

Oh I think it is going to be good

It's definitely NOT bad news. Some revenue is better than no revenue any day of the week. We'll see how this holds up once the near-term enthusiasm settles down.

NEW PR
ShareStrong interest from Saudi investment funds in CEL-SCI, Multikine, and potential joint venture to address the wider Middle East and North Africa marketPatient access and reimbursement/sale in Saudi Arabia within approximately 60 days following filing for Breakthrough Medicine DesignationVIENNA, Va.--(https://www.businesswire.com/)--https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcel-sci.com%2F&esheet=54289130&newsitemid=20250711051288&lan=en-US&anchor=CEL-SCI+Corporation&index=1&md5=7741734321be9a8e482648858015c075(NYSE American: CVM) today announced it has reached an agreement with one of Saudi Arabia’s premier pharmaceutical and healthcare companies for a partnership that spans regulatory and commercial activities for Multikine* (Leukocyte Interleukin, Injection) in the Kingdom of Saudia Arabia. The formal agreement is expected to be signed with the Saudi pharmaceutical partner which will file a Breakthrough Medicine Designation application for Multikine with the Saudi Food and Drug Authority (SFDA) in the coming weeks. According to the SFDA, the response time to a Breakthrough Medicine Designation application is approximately 60 days. Following the granting of the Breakthrough Medicine Designation, Multikine would immediately become available for patient access and reimbursement/sale in Saudi Arabia. Several leading Saudi funds have expressed interest in investing in Multikine, CEL-SCI, and/or a potential joint venture to serve the wider Middle East and North Africa (MENA) market.While CEL-SCI has the option of filing for Breakthrough Medicine Designation directly, the Company made a strategic decision to collaborate with its local partner for the regulatory filing and subsequent commercial distribution in Saudi Arabia. In a prior meeting with the SFDA, the Saudi regulatory agency provided guidance and encouragement to seek breakthrough approval for Multikine in head and neck cancer. CEL-SCI and its Saudi pharma partner believe that Multikine meets all requirements for Breakthrough Medicine Designation as published by the SFDA and are now developing a comprehensive commercialization plan. This plan leverages the partner’s deep expertise in the local healthcare market to rapidly take Multikine through regulatory approvals and into distribution.“We have been directly, and through our representative, https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffirstberlin.com%2F&esheet=54289130&newsitemid=20250711051288&lan=en-US&anchor=First+Berlin&index=2&md5=646d8555da733c89c4db40eee00febdf of Germany and its local Saudi representatives, engaging with medical, regulatory and financial experts in Saudi Arabia in preparation for the regulatory filing to the SFDA. These meetings and the support of leaders in the pharmaceutical industry, healthcare and other sectors in Saudi Arabia, are critical ingredients to bringing our cancer drug to market in the Kingdom. Several meetings have also occurred with some of the most important Saudi Arabian funds that have expressed interest in investing in CEL-SCI directly or the venture between CEL-SCI and our Saudi pharma partner,” stated CEL-SCI CEO, Geert Kersten.Martin Bailey, Managing Director and Founder of First Berlin, commented, “We are seeing a significant level of interest in Multikine and CEL-SCI amongst Saudi investment and healthcare leaders. What CEL-SCI offers is exactly in line with Saudi Arabia’s https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vision2030.gov.sa%2Fen%2Fexplore%2Fexplore-more%2Fnational-biotechnology-strategy&esheet=54289130&newsitemid=20250711051288&lan=en-US&anchor=Vision+2030&index=3&md5=d6b22d41a4a0e9f78b0a9d42239ba55einitiative which seeks to make the Kingdom a global biotech hub. Given the SFDA’s short timeline, this is a near term opportunity for local in-country investors to help bring a much-needed cancer treatment to market while also supporting their nation’s health-tech goals.”Multikine is an immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated head and neck cancer. In the world’s largest head and neck cancer study spanning 20 countries, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone. The 5-year risk of death was halved from 55% to 27%.About the SFDA’s Breakthrough Medicine ProgramThe SFDA Breakthrough Medicine Program aims to facilitate and accelerate development and review of new drugs that address unmet medical needs in the treatment of serious or life-threatening conditions in alignment with Saudi Arabia’s https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.vision2030.gov.sa%2Fen%2Fexplore%2Fexplore-more%2Fnational-biotechnology-strategy&esheet=54289130&newsitemid=20250711051288&lan=en-US&anchor=Vision+2030&index=4&md5=d8a33a2464948437934e80662136997d initiative. The program is voluntary and based on early dialogue with drug developers to optimize development plans and speed up evaluation. The goal is to ensure that promising medicines are available as soon as it can be concluded that the medicines’ benefits justify their risks.Eligibility include having to fulfill all of the following four criteria in order to gain a Breakthrough Medicine Designation:About CEL-SCI CorporationCEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been dosed in over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, inability to receive necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to finalize a partnering agreement and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2024. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

Must be an order imbalance 

Currently halted...

Hit $7.30 pre market!!!

Cel-Sci up $2.60 pre market and going higher

Big new signed contract with Saudi Pharma!!!

Ive heard that Offering is with ThinkEquity is tomorrow AH

Woof

Whats interesting about reading the S-3 that was filed is that they mention Keytruda 6 times and its success. 6 times. But make NO mention of Saudi Arabia.

No SA partner and an S-3

Massive dilution coming

Expect a new Video this week!

A Tale of Two Stocks

CVM

Files a S-3 afterhours on a holiday weekend Offering soon. Whats interesting about reading the prospectus that was filed is that they mention Keytruda 6 times and its success. 6 times. But make NO mention of Saudi Arabia.

They are not getting a partner in SA

IMMX

Looks for a string of news this week

Well funded. Complete response from drug. Trial moving faster. CEO not on twitter fighting shorts

Cheers!

Yep. No cash,... No good way to get the trial going. Maybe IF (and it does seem like a significant if) the Saudi thing works out we get enough capital to get the trial going.
Going way off the farm here. They could be trying for a deal for Saudi to pay them to set up a biologics mfg plant.

Saudi wants into the space. They have nothing, so need anybody who wants to play ball (despite it being 50C outside).

Remember when Geert said the trial would start in Q4-24? Then Q1-25, then Q1/Q2-25, then Q2-25....?

Now its TBD

suckers

Yep. No cash,... No good way to get the trial going. Maybe IF (and it does seem like a significant if) the Saudi thing works out we get enough capital to get the trial going.

Just reward awaits pay/bash employees!!
Karmic Resonance!!!!
👀👀👀

I asked: takes about 18 months for enrollment and he hopes clear effects can be seen in lab during..

I think ERGO recruited about 135 patients during its peak month. So average May be around 90 per month during phase 3. If your saying we have only 1/4 of patients available for this trial that would mean about 22 patients per month or about 10 months for recruitment 

It is not even registered yet. We can make some guesses though.

Compared to the previous P3, it is about 1/4 the size, but the patient population is about 1/4 also. That would suggest a similar enrollment timeline (after backing out the loss of time from the deadbeat CMO). So maybe 3 years to enroll.

There is a huge unknown on completion though. CVM hints at some form of remission being an endpoint for a possible early halt. But they have yet to actually state that. If OS as the endpoint, figure next decade.

Regardless, will never finish if it never starts.

Hasnt started yet

So how long is this 212 trial

Im not a CVM baggie

HA!

Woof!

I believe Geert has just asked for too much regarding the phase. Hopefully.

Only toothless carnie is you looking in the mirror, you must be Geert's pet

If Geert is doing a carnival act, you must be one of his toothless carnies

This is pure garbage

Did you notice NO mention of Saudi anywhere in the PR?

Woof!

Geert doing his carnival act
When phase 3 was finished we hit $45 for a short time then stayed at $25 for months waiting on his final report and then we tanked. His latest PR makes Multikine sound so great so then why did we go to $0.20 before his 3rd reverse split which took us to $6 and now back into the $2s. This company is his personal ATM. I have been here over 10++ years thru 3 R/S and numerous PR's. With his latest PR he makes it seem we aced the last phase 3 so if it was as great as he insinuates why is our stock price where it is. His latest is just more of the same, If Multikine is really that good why hasn't any big Pharma wanting it as they could probably get it for a song and a dance.
"Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS) by 30% compared with standard of care in patients whose tumors expressed higher PD-L1 without demonstrating improvement in overall survival"

So you can say this Summer or when ever 🤩

You've been warned for how many years that this company got into toxic financing?

This company…..😡😡. I sure hope they get some sort of approval to sell a drug at some point. Been invested for maybe a dacade….🤷‍♂️. Give a dog a bone already. …